【Public Health Hotspot】Over 3,000 Cases of Chikungunya Fever! Rapid Testing Technology Powers Precise Prevention and Control, Safeguarding the Health Defense Line!

Recently, cases of chikungunya fever have been reported in Foshan, Guangdong Province, Beijing, and several other regions. The disease has now spread to 119 countries worldwide, prompting an emergency alert from the World Health Organization (WHO)! This is caused by Aedes albopictus (Asian tiger mosquito) and Aedes aegypti A viral disease that spreads through transmission, with symptoms strikingly similar to dengue fever, but with more severe joint pain; in some patients, it may even lead to Months-long joint stiffness and chronic pain , severely impacting quality of life.

Chikungunya fever (CHIKV) It was first discovered in Tanzania, Africa, in 1952. In recent years, driven by global warming and increased international travel, the epidemic has spread to Asia, the Americas, and Europe. In China, southern provinces such as Guangdong, Yunnan, and Fujian, with their humid and hot climates and high mosquito vector densities, have become high-risk areas.

Image source: Yunnan Center for Disease Control and Prevention 

⚠️ Key Symptom Identification:

* Sudden high fever (above 39°C) , lasting 3–7 days

*Severe joint pain (Especially the wrists, knees, and ankles)

*Generalized rash (Similar to measles or dengue fever)

*Headache, muscle aches, conjunctivitis

Due to the high similarity of early symptoms to influenza and dengue fever, the misdiagnosis rate is high; therefore, laboratory testing is crucial for definitive diagnosis!

The incubation period of chikungunya fever typically ranges from 1 to 12 days, with the highest viral load observed in the blood during the early phase of illness (days 1–7). Nucleic acid testing (RT-PCR) performed during this window can rapidly detect viral RNA with a diagnostic accuracy exceeding 85%.

For suspected cases, nucleic acid testing within the first week of illness is the most reliable diagnostic method, helping to prevent missed and misdiagnoses and reducing the risk of further viral transmission.

In the face of the threat posed by chikungunya fever, Guangzhou Weiboxin Biotechnology Co., Ltd. has independently developed Chikungunya Virus Nucleic Acid Detection Kit (PCR–Fluorescent Probe Method) , becoming the “secret weapon” on the CDC front!

🔬 Core Product Advantages: 
✅ High sensitivity: Adopt Multiplex Fluorescent Probe Technology , enabling precise detection of extremely low concentrations of viral RNA and thereby preventing false-negative results. 
✅ Fast and convenient: Compatible with mainstream fluorescence PCR instruments, Results in 2 hours , significantly improving testing efficiency. 
✅ Stable and reliable: The kit is in Can be stored long-term at -20°C , suitable for large-scale screening by testing institutions. 
✅ Strict quality control: Complies with international testing standards to ensure accurate and reliable results.

Currently, this kit has been deployed in Guangdong, Yunnan, and Fujian. Testing institutions in various regions have been put into operation, providing robust technical support for epidemic monitoring, patient management, and prevention and control decision-making.

Currently, there is no specific antiviral treatment or widely available vaccine for chikungunya; management is primarily symptomatic and supportive. Therefore, preventing mosquito bites and ensuring early detection are central to prevention and control!

Insect Key measures for mosquito prevention and control:

*Eliminate standing water: Turn over containers and empty water tanks to eliminate Aedes mosquito breeding.

*Physical protection + chemical mosquito repellent: Long sleeves plus mosquito repellent—double protection with screen doors and mosquito nets.

*High-risk population (Elderly individuals, pregnant women, and those with weakened immune systems) should seek medical attention if they develop symptoms such as fever or joint pain. Test immediately to prevent severe illness. 。

Guangzhou Weiboxin As a domestic molecular diagnostics company, we have long been dedicated to the R&D of infectious disease detection technologies and have successfully launched Dengue fever, Zika virus, chikungunya Mosquito-borne virus detection protocols.

The newly launched Chikungunya virus nucleic acid detection kit and other diagnostic kits not only fill a technological gap in the domestic market but also underscore the company’s social responsibility and commitment to advancing science and technology in response to public health emergencies. Moving forward, Guangzhou Weiboxin will continue to deepen its expertise in the field of precision diagnostics, contributing to global infectious disease prevention and control.

Some reagent protocols are as follows:

For animal disease testing reagents, please choose the Weiboxin brand.

Be aware of Weiboxin Bio All products of!

Official consultation phone numbers: 020-82298089 / 135 3988 6748, Ms. Dai

Overseas Service Hotline (Mobile/WhatsApp/WeChat): +86 18902342201

Email: sara@viuick.com

Guangzhou Weiboxin Biotechnology Co., Ltd. is a provincial-level “Little Giant” high-tech enterprise specializing in the forward R&D, manufacturing, sales, and technical services of diagnostic reagents for animal epidemics. The company is recognized as a “Contract-Honoring and Credit-Keeping Enterprise” by Guangdong Province and a “Provincial Intellectual Property Demonstration Unit.” It also serves as an industry–university–research collaboration base for Guangdong Food and Drug Vocational College and as an executive director unit of the Veterinary Diagnostic and Biological Products Committee of the Guangdong Society of Animal Husbandry and Veterinary Medicine. Furthermore, it has been designated as an innovative, high-potential enterprise by multiple research institutes, including the Entrepreneurship College of Jinan University in Guangdong Province, and has been awarded the titles of “Specialized, Refined, Distinctive, and Innovative” enterprise at both municipal and provincial levels. The company has received the “Most Investment-Valuable Enterprise” award and the annual title of “ASF and Swine Disease Testing Service Provider.” In addition, it holds veterinary drug product approval numbers issued by the Ministry of Agriculture and Rural Affairs: Veterinary Drug Registration No. 191438923 (Fluorescent PCR Test Kit for African Swine Fever Virus), Veterinary Drug Registration No. 191438213 (ELISA Antibody Test Kit for Porcine Reproductive and Respiratory Syndrome Virus), Veterinary Drug Registration No. 191438875 (Blocking ELISA Antibody Test Kit for Classical Swine Fever Virus), and Veterinary Drug Registration No. 191438851 (ELISA Antibody Test Kit for Porcine Circovirus Type 2). The company was awarded the Excellence Prize in the Growth Category of the Biopharmaceutical Industry at the 11th China Innovation and Entrepreneurship Competition, the Provincial Second Prize in the Growth Category of the Nanotechnology Industry Technology Competition within the Science and Technology Innovation and Entrepreneurship Contest, and the National Third Prize in the Growth Category of the National Finals of the Nanotechnology Industry Technology Innovation Special Competition at the China Innovation and Entrepreneurship Competition. It has consecutively received the A-Level Tax Credit Honor Certificate, the Four-Star Trademark and Brand Certification, and the Two-Integration Management System Assessment Certificate each year. Moreover, it has obtained ISO 9001 International Quality Management System Certification, ISO 14001 International Environmental Management System Certification, and GMP certification from the Ministry of Agriculture. Since its establishment, the company has been granted a total of 24 patents, including 5 invention patents, 15 utility model patents, and 4 design patents, as well as more than ten trademarks.

The company boasts robust technical capabilities and a team of world-class professionals, including dozens of masters, doctors, and returnees who studied abroad, as well as numerous senior-title technical experts. Currently, the company’s primary focus is on the research and development of molecular diagnostic reagents. Its core R&D team has developed more than 600 products spanning molecular diagnostics and immunoassays, including public-health–oriented fluorescent PCR test kits, animal disease–control–oriented fluorescent PCR test kits, clinical and research–grade fluorescent quantitative PCR kits, and transgenic–identification test kits (ZL2006). The company has established a nationwide distribution network covering over ten major cities, such as Beijing, Shanghai, Hangzhou, Nanjing, Xi’an, Chongqing, Lanzhou, Zhengzhou, and Qingdao.

Looking ahead, Weiboxin will remain steadfast in its commitment to continuously enhance product quality and service standards. Leveraging a rapid and efficient research platform and abundant biomedical resources, we will conduct extensive and in-depth R&D and scientific research in the biomedical field, thereby contributing to human health and advancing life sciences. Quality is our lifeline; innovation is our soul. Upholding this guiding principle, we will relentlessly strive to become the premier supplier of rapid diagnostic reagents and instruments.